000294453 001__ 294453
000294453 005__ 20250107161238.0
000294453 0247_ $$2doi$$a10.1002/ijc.35205
000294453 0247_ $$2pmid$$apmid:39511728
000294453 0247_ $$2ISSN$$a0020-7136
000294453 0247_ $$2ISSN$$a1097-0215
000294453 0247_ $$2altmetric$$aaltmetric:170400759
000294453 037__ $$aDKFZ-2024-02278
000294453 041__ $$aEnglish
000294453 082__ $$a610
000294453 1001_ $$00000-0002-1357-5896$$aReichmann, Robin$$b0
000294453 245__ $$aSex- and site-specific associations of circulating lipocalin 2 and incident colorectal cancer: Results from the EPIC cohort.
000294453 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000294453 3367_ $$2DRIVER$$aarticle
000294453 3367_ $$2DataCite$$aOutput Types/Journal article
000294453 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736262711_26416
000294453 3367_ $$2BibTeX$$aARTICLE
000294453 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294453 3367_ $$00$$2EndNote$$aJournal Article
000294453 500__ $$a2025 Mar 1;156(5):930-942
000294453 520__ $$aExperimental research has uncovered lipocalin 2 (LCN2) as a novel biomarker implicated in the modulation of intestinal inflammation, metabolic homeostasis, and colon carcinogenesis. However, evidence from human research has been scant. We, therefore, explored the association of pre-diagnostic circulating LCN2 concentrations with incident colorectal cancer (CRC) in a nested case-control study within the in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. LCN2 was measured in 1267 incident CRC cases matched to 1267 controls using incidence density sampling. Conditional logistic regression was used to estimate incidence rate ratios (IRRs) and 95% confidence intervals (95% CIs) according to tumor subsite and sex. Weighted Cox proportional hazard regression was used to explore associations by adiposity status. In multivariable-adjusted analyses, the IRR [95% CI] per doubling in LCN2 concentration was 1.16 [0.98-1.37] for CRC overall, 1.26 [1.00-1.59] for colon cancer, and 1.08 [0.85-1.38] for rectal cancer. The association for colon cancer was more pronounced in women (IRR [95% CI], 1.66 [1.20-2.30]) and for proximal colon cancer (IRR [95% CI], 1.96 [1.15-3.34]), whereas no association was seen in men and distal colon cancer. The association for colon cancer was positive in individuals with high waist circumference (hazard ratio [95% CI], 1.69 [1.52-1.88]) and inverse in individuals with low waist circumference (hazard ratio [95% CI], 0.86 [0.76-0.98], P interaction<0.01). Overall, these data suggest that pre-diagnostic LCN2 concentrations were positively associated with colon cancer, particularly occurring in the proximal colon, in women and among individuals with abdominal adiposity.
000294453 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000294453 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294453 650_7 $$2Other$$aEPIC
000294453 650_7 $$2Other$$acolorectal cancer
000294453 650_7 $$2Other$$aimmunity
000294453 650_7 $$2Other$$alipocalin 2
000294453 650_7 $$2Other$$ametabolism
000294453 7001_ $$00000-0001-7877-205X$$aNimptsch, Katharina$$b1
000294453 7001_ $$00000-0003-1568-767X$$aPischon, Tobias$$b2
000294453 7001_ $$00000-0001-5472-6761$$aGunter, Marc J$$b3
000294453 7001_ $$00000-0002-0573-1852$$aJenab, Mazda$$b4
000294453 7001_ $$00000-0002-4535-3788$$aEriksen, Anne Kirstine$$b5
000294453 7001_ $$00000-0003-4385-2097$$aTjonneland, Anne$$b6
000294453 7001_ $$aJanke, Jürgen$$b7
000294453 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b8$$udkfz
000294453 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b9$$udkfz
000294453 7001_ $$00000-0002-0830-5277$$aSchulze, Matthias B$$b10
000294453 7001_ $$00000-0002-3975-5596$$aEichelmann, Fabian$$b11
000294453 7001_ $$00000-0002-5758-9069$$aMasala, Giovanna$$b12
000294453 7001_ $$00000-0001-5201-172X$$aSieri, Sabina$$b13
000294453 7001_ $$00000-0003-4224-7821$$aPasanisi, Fabrizio$$b14
000294453 7001_ $$00000-0003-2666-414X$$aTumino, Rosario$$b15
000294453 7001_ $$00000-0002-7152-6902$$aGiraudo, Maria Teresa$$b16
000294453 7001_ $$00000-0002-6927-3360$$aRothwell, Joseph$$b17
000294453 7001_ $$00000-0001-7157-419X$$aSeveri, Gianluca$$b18
000294453 7001_ $$00000-0003-0672-8847$$aJakszyn, Paula$$b19
000294453 7001_ $$00000-0003-4817-0757$$aSanchez-Perez, Maria Jose$$b20
000294453 7001_ $$00000-0003-3986-7026$$aAmiano, Pilar$$b21
000294453 7001_ $$00000-0002-6700-0780$$aColorado-Yohar, Sandra M$$b22
000294453 7001_ $$aGuevara, Marcela$$b23
000294453 7001_ $$00000-0002-9692-101X$$avan Guelpen, Bethany$$b24
000294453 7001_ $$00000-0002-0442-3284$$aAglago, Elom K$$b25
000294453 7001_ $$00000-0001-6517-1300$$aHeath, Alicia K$$b26
000294453 7001_ $$aSmith-Byrne, Karl$$b27
000294453 7001_ $$aWeiderpass, Elisabete$$b28
000294453 7001_ $$00000-0002-1275-1827$$aAleksandrova, Krasimira$$b29
000294453 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.35205$$gp. ijc.35205$$n5$$p930-942$$tInternational journal of cancer$$v156$$x0020-7136$$y2025
000294453 909CO $$ooai:inrepo02.dkfz.de:294453$$pVDB
000294453 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000294453 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000294453 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000294453 9141_ $$y2024
000294453 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000294453 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000294453 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000294453 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000294453 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000294453 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000294453 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000294453 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000294453 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000294453 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000294453 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000294453 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000294453 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000294453 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000294453 980__ $$ajournal
000294453 980__ $$aVDB
000294453 980__ $$aI:(DE-He78)C020-20160331
000294453 980__ $$aUNRESTRICTED